Corvus Pharmaceuticals (CRVS) Other Non-Current Assets (2015 - 2026)

Corvus Pharmaceuticals' Other Non-Current Assets history runs 11 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 173.45% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 173.45% YoY), while the FY2025 annual figure was $855000.0, up 35.28% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $1.7 million, up from $855000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $1.7 million in Q1 2026, with the low at $89000.0 in Q3 2023.
• The 5-year median for Other Non-Current Assets is $236000.0 (2022), against an average of $415823.5.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets tumbled 78.11% in 2022, then surged 610.11% in 2024.
• Corvus Pharmaceuticals' Other Non-Current Assets stood at $129000.0 in 2022, then tumbled by 31.01% to $89000.0 in 2023, then soared by 610.11% to $632000.0 in 2024, then jumped by 35.28% to $855000.0 in 2025, then jumped by 101.17% to $1.7 million in 2026.
• Business Quant data shows CRVS's Other Non-Current Assets at $1.7 million in Q1 2026, $855000.0 in Q4 2025, and $852000.0 in Q3 2025.